Clinical trials: Tumor Immunity
Gastric Cancer
InteGRAtive Analysis of TuMor, Microenvironment, ImmunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer
Multicentric, exploratory, non-pharmacologic, retrospective/prospective, translational study aiming to identify the molecular, cellular and psychological-sociological variables predictive of response to chemotherapy in gastric…
- Trial name
- GRAMMY (NCT04842916)
- Where
- 5 sites in France, Greece and 1 more
- Volunteers
- 250 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Lung Neoplasm Malignant
Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy
Any kind of anatomical lung resection for lung cancer with curative intent has to be accompanied by formal mediastinal lymph node dissection.
- Trial name
- NCT04778826
- Testing
- Lymphadenectomy
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Otto Wagner Hospital
Children With Cancer, SARS-CoV-2 Infection
Persistent SARS-CoV-2 Infection in Children With Cancer and Impaired Immune Responsiveness
The main goal of this study is to characterize the adaptive immune responses to SARS-CoV-2 infection in a cohort of children with cancer and impaired immune responsiveness and prolonged viral shedding of SARS-CoV-2, and to…
- Trial name
- NCT05172063
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Recurrent Melanoma, Stage IA Melanoma
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma.
- Conditions
- Recurrent Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage IIA Melanoma
- Trial name
- NCT00003895
- Testing
- HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1
This is an Open-label, single-arm, phase II study of ipilimumab in patients with spontaneous preexisting immune response to NY-ESO-1.
- Trial name
- CTLA4 NY-ESO-1 (NCT01216696)
- Testing
- ipilimumab
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Cancer
Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology: Potential Biomarker for Emerging Immunotherapies
Purposes of this study are : Characterization of polyfunctionality of anti-tumor T lymphocytes using in vitro inhibition of PD-1/PDL-1 pathway Study and comparison of polyfunctionality of anti-tumor T lymphocytes in cohorts of…
- Trial name
- POLYTCANCER (NCT02880046)
- Volunteers
- 90 people
- Sponsor
- Central Hospital, Nancy, France
Breast Cancer
Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer
This is a prospective, non-randomized study which aims to evaluate the response to a neoadjuvant chemotherapy according to the the antitumor immune response in localized breast cancer. 40 patients will be enrolled in the study.
- Trial name
- BREAST IMMUN (NCT01440413)
- Testing
- Blood and tumor sample
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Leon Berard
Cervical Intraepithelial Neoplasia
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
The main purpose of this study was to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals SA (GSK)'s investigational adjuvanted human papillomavirus (HPV) vaccine formulations.
- Trial name
- NCT05496231
- Testing
- HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation
- Where
- 68 sites in United States, Bulgaria and 6 more
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML)
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation
The purpose of this study is to determine the safety and effectiveness of administering Wilms tumor gene 1 (WT1) cancer peptides.
- Conditions
- Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
- Trial name
- WT-1 (NCT00672152)
- Testing
- WT1 derived peptides
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Michael Morse, MD
Acute Lymphocytic Leukemia
Effect of Oral Supplementation With a Fibre Enriched Paediatric Sip Feed For Children With Acute Lymphocytic Leukemia
This is a randomised, controlled, open-label intervention study. It is hypothesized that supplementation with a fibre enriched sip feed will improve the nutritional status, gut microbiota and quality of life (QOL) of children…
- Trial name
- NCT01600781
- Testing
- NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Lung Cancer, Effects of Chemotherapy
Intestinal Microflora in Lung Cancer After Chemotherapy
Probiotics modulate the gut microflora and immune status in lung cancer who need chemotherapy.
- Conditions
- Lung Cancer, Effects of Chemotherapy, Tumor Immunity, Malnutrition
- Trial name
- NCT02771470
- Testing
- Probiotics
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Shandong University
Early Breast Cancer
Aromatherapy in the Treatment of Early Breast Cancer
Breast cancer is a major threat to women's health, and chemotherapy is one of the most important treatment method. Chemotherapy is cytotoxic , and has a positive tumor immune effect.
- Trial name
- NCT06435104
- Testing
- neoadjuvant chemotherapy, aromatherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ovarian Cancer, Triple-Negative Breast Cancer
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer…
- Conditions
- Ovarian Cancer, Triple-Negative Breast Cancer, Head and Neck Cancer, Cervical Cancer
- Trial name
- SCANDARE (NCT03017573)
- Testing
- Tumor biopsies / Tumor surgery, Blood withdrawal
- Where
- 6 sites in France
- Volunteers
- 1,050 people
- Sponsor
- Institut Curie
Urothelial Carcinoma, Melanoma
SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma
The study is an exploratory prospective, single center study with correlative endpoints. The study will investigate the association of tumor cGAS STING signaling with SAbR.
- Conditions
- Urothelial Carcinoma, Melanoma, Cervical Carcinoma in Situ
- Trial name
- NCT02986867
- Testing
- SAbR Treatment of Lesions
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Texas Southwestern Medical Center
Bladder Cancer
Intravesical BCG Administration to Patients With Invasive Bladder Cancer
Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment response) BCG intravesically followed by a cystectomy.
- Trial name
- NCT02365207
- Testing
- BCG strain of Mycobacterium bovis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Neoplasms, Malignant Solid Tumors
Cancer Vaccine Targeting Brachyury Protein in Tumors
Background: Cancer vaccines are being developed to help teach the body's immune system to attack and destroy cancer cells. A new vaccine being tested targets Brachyury protein.
- Conditions
- Neoplasms, Malignant Solid Tumors, Colon Neoplasms, Adenocarcinoma
- Trial name
- NCT01519817
- Testing
- GI-6301 (Yeast Brachyury Vaccine)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Melanoma, Mucosal Melanoma
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability.
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin
- Trial name
- NCT07600476
- Testing
- KUP-101A
- Where
- 3 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Kupando GmbH
Breast Cancer
A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
The hypothesis of the CA048-001 Phase 1 clinical trial is targeting multiple mechanisms involved in generating and maintaining antitumor immune response will lead to a tolerable and robust anti-tumor response.
- Trial name
- NCT04132817
- Testing
- Nivolumab, Ipilimumab, Nab-paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine
In this study, a melanoma vaccine (5 melanoma peptides) is given with either Montanide or dendritic cells as adjuvants. This randomized trial will establish the safety of both vaccines and compare the 2 vaccine adjuvants in their…
- Trial name
- NCT00124124
- Testing
- KLH; Peptides; Dendritic Cells, KLH, peptides plus Montanide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Dr. Nina Bhardwaj
Adjuvant Chemotherapy, Colon Cancer
Modulation of Immune Response by Oral Zinc Supplementation in Chemotherapy for Colon Cancer
In leukocytes of patients undergoing adjuvant chemotherapy for colon cancer treatment: a)identify genes modulated by oral supplementation of zinc; b) evaluate the effects of oral zinc supplementation on humoral immunity and…
- Conditions
- Adjuvant Chemotherapy, Colon Cancer, Immunity
- Trial name
- NCT01261962
- Testing
- zinc
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo